SynthesisRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2011
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
Synthesis in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy.Current oncology (Toronto, Ont.) · 2022Pooled it
- Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?World journal of gastroenterology · 2014Pooled it
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015Trial
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.The Lancet. Oncology · 2013Trial
- Superior tumor cell killing by oxygen ion beam irradiation compared to carbon ions and photons in pancreatic Cancer cells - An in vitro investigation.Clinical and translational radiation oncology · 2026Article
- Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer.Gastroenterology and hepatology from bed to bench · 2025Review
- An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer.Frontiers in oncology · 2022Review
- Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy.Journal of gastrointestinal oncology · 2021Article
- Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.International journal of molecular sciences · 2021Article
- Review
- Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.Annals of surgery · 2019Article
- Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.European journal of nuclear medicine and molecular imaging · 2019Article
- A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy andEuropean journal of nuclear medicine and molecular imaging · 2018Article
- Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression.World journal of gastroenterology · 2017Review
- Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.Cancer research and treatment · 2016Article
- Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy.International journal of molecular sciences · 2016Review
- A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer.Gut and liver · 2016Article
- Meta-analyses of treatment standards for pancreatic cancer.Molecular and clinical oncology · 2016Article
- Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.World journal of clinical oncology · 2016Review
- Update on the management of pancreatic cancer: surgery is not enough.World journal of gastroenterology · 2015Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWhether gemcitabine based chemoradiotherapy (GEM-based CRT) is superior to 5-fluorouracil based chemoradiotherapy (5-FU-based CRT) for locally advanced pancreatic cancer (LAPC) remains uncertain. The aim of the present study was to evaluate the effect of GEM-based CRT compared with 5-FU-based CRT.
methodsElectronic database including Medline, Embase, Cochrane controlled trials register, PubMed (update to December 2010) and manual bibliography searches were carried out. A meta-analysis of all randomized clinical trials (RCTs) or other comparative studies comparing GEM-based CRT and 5-FU-based CRT were performed.
resultsThree RCTs and one retrospective comparative study including 229 patients were assessed. Meta-analysis showed survival advantage of GEM-based CRT compared with 5-FU-based CRT for 12-month (12-mo) survival rates (SRs) (RR=1.54, 95% CI 1.05-2.26, p=0.03). Moreover, there were also trends of benefit for SR after 6-months (RR 1.13, 95% CI 0.98-1.30, p=0.09) and 24-months (24-mo: RR 2.41, 95% CI 0.90-6.48, p=0.08), though the trends did not reach statistical significance. More frequent severe acute hematologic toxicities were found in the GEM-based CRT group.
conclusionsThe meta-analysis found that GEM-based CRT was better than 5-FU-based CRT in the treatment of LAPC, especially for 12-mo SRs. However, the acute toxicity should be carefully regarded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.